CRANFORD, N.J., March 10, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology?focused biopharmaceutical company and majority?owned subsidiary of Citius ...
15 小时
Citius Oncology, Inc.: Citius Oncology Announces Positive Topline Results from Investigator ...
Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果